KDNY   $40.39  0.20% Market Closed

Chinook Therapeutics Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-08-06 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-08-05 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-08-04 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: exit from the overbought zone.

2023-08-04 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-08-03 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-03 Signal in MACD changed from bearish reversal to bullish recovery. Oscillator MACD is in the positive territory it's lower than the signal line and grows. These factors mean that positive mood prevails, but this trend does not have a significant strength. Last signal: exit from the overbought zone.


Current temperature: 0.72
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 7
Target Price Mean 39.43
Mean unverified/preliminary 39.43 / 39.43
Target Price Low / High 32.00 / 42.00
Median / STD DEV 40.00 / 3.36
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy None ActivelyBuy
rsi Sell None ActivelyBuy
macd None None None
stoch ActivelyBuy None None
ma20 None Sell ActivelyBuy
ma50 None None None
ma100 Buy None None
Candlestick PatternAug. 10, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US16961L1061
ceo Mr. Eric L. Dobmeier J.D.
Website https://www.chinooktx.com
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.